(Total Views: 539)
Posted On: 12/29/2020 9:31:05 AM
Post# of 72444
Zdubble17, found this link from within your link interesting also:
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 45 million infected individuals worldwide as of October 30, 2020. Due to the increasing prevalence of COVID-19, key players operating in the Methicillin-resistant staphylococcus aureus (MRSA) drugs market are focusing on research and development of novel products to support and combat the effect of COVID-19. COVID-19 pandemic has impacted the global economy and in turn, the Methicillin-resistant staphylococcus aureus (MRSA) drugs market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the third quarter of 2020
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Restraint
Patent expiration of currently existing MRSA drugs will lead to large revenue loss for key players due to introduction of low cost generic drugs. This is expected to have negative impact on Methicillin-resistant staphylococcus aureus drugs market growth. For instance, in December 2015, various key players such as Camber Pharmaceuticals, Mylan N.V., and Teva Pharmaceutical Industries Ltd. launched generic version of Zyvox (Linezolid) which is used to treat susceptible Gram-positive infections (for example, Staphylococcus and Streptococcus spp.).
Moreover, declining patient burden, and product recalls to treat MRSA drugs of some major companies are some of the factors that are expected to hamper the market growth over the forecast period.
Key Players
Major players operating in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
Read Detailed Index of full Research Study at: https://www.coherentmarketinsights.com/market...arket-1538
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 45 million infected individuals worldwide as of October 30, 2020. Due to the increasing prevalence of COVID-19, key players operating in the Methicillin-resistant staphylococcus aureus (MRSA) drugs market are focusing on research and development of novel products to support and combat the effect of COVID-19. COVID-19 pandemic has impacted the global economy and in turn, the Methicillin-resistant staphylococcus aureus (MRSA) drugs market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the third quarter of 2020
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - Restraint
Patent expiration of currently existing MRSA drugs will lead to large revenue loss for key players due to introduction of low cost generic drugs. This is expected to have negative impact on Methicillin-resistant staphylococcus aureus drugs market growth. For instance, in December 2015, various key players such as Camber Pharmaceuticals, Mylan N.V., and Teva Pharmaceutical Industries Ltd. launched generic version of Zyvox (Linezolid) which is used to treat susceptible Gram-positive infections (for example, Staphylococcus and Streptococcus spp.).
Moreover, declining patient burden, and product recalls to treat MRSA drugs of some major companies are some of the factors that are expected to hamper the market growth over the forecast period.
Key Players
Major players operating in the global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
Read Detailed Index of full Research Study at: https://www.coherentmarketinsights.com/market...arket-1538
(1)
(0)
